From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and multiple myeloma, covering both fundamental research and clinical applications. The conference also addressed key challenges in diagnosis and treatment, fostering in-depth discussions among specialists.At the conference, Hematology Frontier had the privilege of interviewing the conference chair, Professor Jun Ma, Director of the Harbin Institute of Hematology & Oncology. He shared key highlights of the event, CSCO’s initiatives in translating research into clinical practice, and the committee’s strategic direction for the future.
Pushing the Boundaries of Hematologic Cancer Treatment
This year’s CSCO Hematologic Oncology Conference convened experts from the CSCO Leukemia, Lymphoma, and Multiple Myeloma committees and formally established the preparatory committee for Myelodysplastic Syndromes (MDS). The conference showcased China’s latest achievements in hematologic cancer research and treatment while integrating insights from recent meetings of the American Society of Hematology (ASH) and the European Hematology Association (EHA). Experts from the U.S., Europe, and Hong Kong were also invited to share their expertise and exchange ideas.
The conference drew a wide range of participants, including leading researchers in hematologic malignancies, specialists in translational medicine and biopharmaceuticals, and representatives from government agencies, regulatory bodies, and healthcare policy organizations. Under the theme “Collaboration, Innovation, and Practicality,” the event reaffirmed its patient-centered mission by introducing cutting-edge international treatment strategies and promoting standardized care.
A major highlight was the finalization of eight clinical guidelines, covering the latest updates in leukemia, lymphoma, and multiple myeloma management. The conference also explored advancements in translational medicine and biomedical technologies, with a strong focus on improving patient survival and working toward higher cure rates.
Updating Guidelines to Accelerate Global Integration
Over the past year, CSCO has made significant strides in updating its clinical guidelines for lymphoma, leukemia, allogeneic hematopoietic stem cell transplantation, tumor-related anemia, and chemotherapy-induced thrombocytopenia. Additionally, new guidelines were introduced for multiple myeloma, CAR-T cell therapy, and cancer therapy-related liver injury, ensuring that medical professionals across China have access to the latest, evidence-based treatment protocols.
China’s advancements in cellular therapy and transplantation have positioned the country at the forefront of the field. Looking ahead, we hope to see a new generation of young scholars continue the legacy of their predecessors, driving Chinese hematology research and treatment to even greater heights. Our goal is to bring China’s voice to the global stage, allowing more experts worldwide to learn from China’s experience.
Innovation is the key to progress. The emergence of novel therapies is essential to providing hematologic cancer patients with long-term survival and even the possibility of a cure. With this vision in mind, we must work together to push the boundaries of science and treatment.
Looking Ahead: Strengthening Drug Innovation and Global Collaboration
Leukemia, lymphoma, and multiple myeloma are among the most prevalent hematologic malignancies, particularly in older adults over 60 years of age. While complete remission remains an ultimate goal, our current focus is to help patients achieve long-term survival and maintain a quality of life comparable to that of healthy individuals. For lymphoma and multiple myeloma patients, adopting a chronic disease management approach—similar to how hypertension and diabetes are treated—can significantly improve outcomes and overall well-being.
China has made remarkable progress in the research and treatment of hematologic malignancies, gradually aligning with international standards. However, challenges remain:
- Insufficient development of innovative drugs, particularly first-in-class therapies originating from China.
- Reduced international exchange in recent years, partly due to the pandemic.
Moving forward, our focus will be on two key priorities:
- Accelerating the development of innovative, homegrown drugs to bridge the gap with leading global therapies.
- Reviving and strengthening international academic collaborations with key organizations such as ASH, EHA, and the Japanese Society of Hematology (JSH). By fostering closer ties with these institutions, we aim to enhance China’s contributions to hematologic research and ultimately improve patient care worldwide.
About Professor Jun Ma
Professor Jun Ma is a leading authority in hematologic oncology. He serves as:
- Director, Harbin Institute of Hematology & Oncology
- Chair, CSCO Supervisory Board
- Vice Chair, Asian Society of Clinical Oncology
- Chair, CSCO Leukemia Expert Committee
- Head, National Health Commission’s Lymphoma Specialty Development Project
- Editor-in-Chief, Leukemia & Lymphoma Journal
- Former Chair, CSCO
- Former Vice Chair, Chinese Medical Association Hematology Branch
His contributions continue to shape China’s hematologic oncology landscape, bridging the gap between research and clinical application while championing China’s role on the international stage.
